查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1433534

抗生素抗药性市场规模、份额、趋势分析报告：按疾病、病原体、药物类别、作用机制、通路、地区、细分市场预测，2024-2030

Antibiotic Resistance Market Size, Share & Trends Analysis Report By Disease (cUTI, CDI), By Pathogen, By Drug Class, By Mechanism of Action, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10个工作天内

价格

抗生素抗药性市场成长与趋势：

Grand View Research, Inc.最新报告显示，预计2030年全球抗生素抗药性市场规模将达到124.8亿美元，2024年至2030年复合年增长率为5.27%。

由于滥用和过度使用抗生素而导致的抗生素抗药性感染疾病的增加是市场成长的主要驱动力。此外，全球患者数量的增加以及与疾病治疗相关的高成本预计将在预测期内促进市场成长。

革兰氏阴性感染疾病的盛行率正以惊人的速度增加。市面上这些感染疾病的治疗选择较少。由于未满足的需求很高，因此对新治疗方法的需求也很高，这就是为什么中小型製药公司正在积极致力于开发新治疗方法。此外，政府和其他机构也支持研究工作，以推动创新治疗方法的发展。

几家中型生技公司正进入该领域，针对抗生素抗药性感染疾病提供标靶治疗。各种製造商正在开发针对较小族群的治疗方法，特别是针对抗药性感染疾病。

美国政府与 BARDA 合作，支持多家公司协助开发抗生素抗药性疾病的新治疗方法。 BARDA 也与 GSK、Tetraphase、Basilea 和Astra Zeneca等製药公司合作。许多国家和国际组织成立了专门小组和联盟来监测和研究抗药性感染疾病的模式。

例如，世卫组织推出了全球抗生素抗药性监测系统（GLASS），以在全球范围内监测抗生素抗药性感染疾病。同样，加拿大公共卫生局实施了加拿大抗菌素抗药性监测系统（CARSS），以调查国家层级的抗药性感染模式。

然而，根据世界卫生组织 2023 年 3 月发布的审查，抗生素管道活动有限，2017 年至 2021 年间仅核准了12 种新抗生素。审查还发现，目前正在开发的新候选药物只有 27 种，其中只有 6 种被认为具有足够的“创新性”，能够克服世界卫生组织定义的抗生素抗药性。

抗生素抗药性市场报告亮点

  • 预计到2023年，cUTI将占据最大的市场占有率，并在未来几年保持其在全球市场的主导地位。
  • 预计组合药物在预测期内将以最快的复合年增长率成长。
  • 到 2023 年，北美将主导抗生素抗药性产业。美国国家行动计画为解决抗药性革兰氏阳性和阴性感染疾病的巨大负担而设定的目标是推动市场的主要因素。
  • 由于抗生素的过度消费、技术进步以及对抗生素抗药性检测、治疗和管理的认识不断提高，亚太地区将在预测期内出现最快的增长。

目录

第一章调查方法和范围

第 2 章执行摘要

第三章抗生素抗药性市场变数、趋势和范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 抗生素抗药性市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析

第四章抗生素抗药性市场：疾病估计与趋势分析

  • 2023年及2030年疾病市场占有率
  • 细分仪表板
  • 按疾病分類的全球抗生素抗药性市场展望
  • 2018年至2030年市场规模、预测与趋势分析如下

第五章抗生素抗药性市场：发病机制估计与趋势分析

  • 2023 年和 2030 年病原体市场占有率
  • 细分仪表板
  • 按病原体分類的全球抗生素抗药性市场展望
  • 2018年至2030年市场规模、预测与趋势分析如下

第六章抗生素抗药性市场：药物类别的估计和趋势分析

  • 2023年及2030年医药类市场占有率
  • 细分仪表板
  • 按药物类别分類的全球抗生素抗药性市场展望
  • 2018年至2030年市场规模、预测与趋势分析如下

第七章 抗生素抗药性市场：效果评估与趋势分析

  • 2023年及2030年市场占有率行动机制
  • 细分仪表板
  • 按作用机制分類的全球抗生素抗药性市场展望
  • 2018年至2030年市场规模、预测与趋势分析如下

第八章抗生素抗药性市场：分销管道估计和趋势分析

  • 2023 年及 2030 年分销通路市场占有率
  • 细分仪表板
  • 按分销管道分類的全球抗生素抗药性市场展望
  • 2018年至2030年市场规模、预测与趋势分析如下

第九章抗生素抗药性市场：区域估计和趋势分析

  • 2023 年及 2030 年区域市场占有率分析
  • 区域市场仪表板
  • 全球区域市场概况
  • 2018-2030年市场规模及预测趋势分析：
  • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麦
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东/非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第10章竞争形势

  • 主要市场参与企业的最新趋势和影响分析
  • 公司/竞争对手分类
  • 供应商形势
    • List of key distributors and channel partners
    • Key customers
    • Key company market share analysis, 2023
    • Melinta Therapeutics
    • Basilea Pharmaceutica Ltd.
    • Tetraphase Pharmaceuticals
    • Theravance Biopharma
    • WOCKHARDT
    • Paratek Pharmaceuticals, Inc.
    • Seres Therapeutics
    • ACHAOGEN, INC.
    • Entasis therapeutics
    • AbbVie
    • Merck &Co. Inc.
Product Code: GVR-2-68038-663-9

Antibiotic Resistance Market Growth & Trends:

The global antibiotic resistance market size is expected to reach USD 12.48 billion by 2030, registering a CAGR of 5.27% from 2024 to 2030, according to a new report by Grand View Research, Inc. Rise in the number of antibiotic-resistant infections due to misuse or overuse of antibiotics is a major factor attributing to market growth. Moreover, the increasing patient base across the globe and high costs associated with the treatment of diseases is anticipated to boost the market growth over the forecast period.

The prevalence of gram-negative infections is increasing at an alarming rate. These infections have lesser treatment options available in the market. The high unmet needs result in high demand for new therapies and, therefore, small and medium-sized pharmaceutical companies are actively involved in the development of novel treatment options. Moreover, the government and other organizations are also aiding research activities to drive the development of innovative therapies.

Multiple mid-level biotechnology companies have entered the arena with targeted therapies for antibiotic-resistant infections. Various manufacturers are developing therapies, especially for drug-resistant infections, that target a smaller population subset.

The U.S. government in alliance with BARDA is supporting several companies to boost the development of new therapies for antibiotic-resistant diseases. BARDA has also been associated with pharmaceutical companies such as GSK; Tetraphase; Basilea; Astra Zeneca; and many more. Many countries and international organizations have formed dedicated groups or alliances to monitor and study the pattern of drug-resistant infections.

For instance, the WHO has introduced the Global Antimicrobial Resistance Surveillance System (GLASS) to monitor antibiotic-resistant infections at a global level. Similarly, the Public Health Agency of Canada has introduced the Canadian Antimicrobial Resistance Surveillance System (CARSS) to study drug-resistant infections pattern at the country level.

However, according to a review published by WHO in March 2023, the antibiotics pipeline activities are limited, with only 12 new antibiotics being approved between 2017 and 2021. The review further stated that there are only 27 new candidates under development, out of which only 6 are considered "innovative" enough to be capable of overcoming antibiotic resistance as defined by WHO.

Antibiotic Resistance Market Report Highlights:

  • In 2023, cUTI accounted for the largest market share and is anticipated to maintain its dominance in the global market in the coming years
  • Combination drugs are expected to grow at the fastest CAGR over the forecast period
  • North America dominated the antibiotic resistance industry in 2023. The target goals set by the U.S. national action plan in response to the significant burden of resistant gram-positive and negative infections is the key factor driving the market
  • Asia Pacific is set to witness the fastest growth over the forecast period due to excessive consumption of antibiotics, advancements in technology, and growing awareness about antibiotic resistance testing, treatment, & management of the same.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Disease
    • 1.2.2. Pathogen
    • 1.2.3. Drug Class
    • 1.2.4. Mechanism of Action
    • 1.2.5. Distribution Channel
    • 1.2.6. Regional scope
    • 1.2.7. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary Distribution Channels
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Distribution Channels
  • 1.9. List of Primary Distribution Channels
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Disease
    • 2.2.2. Pathogen
    • 2.2.3. Drug Class
    • 2.2.4. Mechanism of Action
    • 2.2.5. Distribution Channel
    • 2.2.6. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Antibiotic Resistance Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing burden of antibiotic-resistant infections
      • 3.2.1.2. Growing need for new antibiotic therapies
      • 3.2.1.3. Rising public health concern and awareness
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High cost of therapeutics
  • 3.3. Antibiotic Resistance Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Antibiotic Resistance Market: Disease Estimates & Trend Analysis

  • 4.1. Disease Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Antibiotic Resistance Market by Disease Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. cUTI (Complicated Urinary Tract Infections)
      • 4.4.1.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.2. CDI (Clostridioides difficile Infection)
      • 4.4.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.3. ABSSSI (Acute bacterial skin and skin structure infections)
      • 4.4.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.4. HABP (Hospital-acquired bacterial pneumonia)
      • 4.4.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.5. CABP (Community-acquired pneumonia)
      • 4.4.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.6. cIAI (Complicated intra-abdominal infection)
      • 4.4.6.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.7. BSI (Bloodstream infection
      • 4.4.7.1. Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Antibiotic Resistance Market: Pathogen Estimates & Trend Analysis

  • 5.1. Pathogen Market Share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Antibiotic Resistance Market by Pathogen Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. E. coli
      • 5.4.1.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 5.4.2. K. pneumoniae
      • 5.4.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 5.4.3. P. aeruginosa
      • 5.4.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 5.4.4. S. aureus
      • 5.4.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 5.4.5. A. baumannii
      • 5.4.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 5.4.6. S. pneumoniae
      • 5.4.6.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 5.4.7. H. influenzae
      • 5.4.7.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 5.4.8. C. difficile
      • 5.4.8.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 5.4.9. E. faecium
      • 5.4.9.1. Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Antibiotic Resistance Market: Drug Class Estimates & Trend Analysis

  • 6.1. Drug Class Market Share, 2023 & 2030
  • 6.2. Segment Dashboard
  • 6.3. Global Antibiotic Resistance Market by Drug Class Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 6.4.1. Oxazolidinones
      • 6.4.1.1. Market estimates and forecasts, 2018 to 2030 (USD million)
    • 6.4.2. Lipoglycopeptides
      • 6.4.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.4.3. Tetracyclines
      • 6.4.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.4.4. Combination therapies
      • 6.4.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.4.5. Cephalosporins
      • 6.4.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.4.6. Others
      • 6.4.6.1. Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 7. Antibiotic Resistance Market: Mechanism of Action Estimates & Trend Analysis

  • 7.1. Mechanism of Action Market Share, 2023 & 2030
  • 7.2. Segment Dashboard
  • 7.3. Global Antibiotic Resistance Market by Mechanism of Action Outlook
  • 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 7.4.1. Protein Synthesis Inhibitors
      • 7.4.1.1. Market estimates and forecasts, 2018 to 2030 (USD million)
    • 7.4.2. Cell Wall Synthesis Inhibitors
      • 7.4.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.3. RNA Synthesis Inhibitors
      • 7.4.3.1. Market estimates and forecasts, 2018 to 2030 (USD million)
    • 7.4.4. DNA Synthesis Inhibitors
      • 7.4.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.5. Others
      • 7.4.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 8. Antibiotic Resistance Market: Distribution Channel Estimates & Trend Analysis

  • 8.1. Distribution Channel Market Share, 2023 & 2030
  • 8.2. Segment Dashboard
  • 8.3. Global Antibiotic Resistance Market by Distribution Channel Outlook
  • 8.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 8.4.1. Hospital Pharmacies
      • 8.4.1.1. Market estimates and forecasts, 2018 to 2030 (USD million)
    • 8.4.2. Retail Pharmacies
      • 8.4.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.4.3. Online Pharmacies
      • 8.4.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 9. Antibiotic Resistance Market: Regional Estimates & Trend Analysis

  • 9.1. Regional Market Share Analysis, 2023 & 2030
  • 9.2. Regional Market Dashboard
  • 9.3. Global Regional Market Snapshot
  • 9.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 9.5. North America
    • 9.5.1. U.S.
      • 9.5.1.1. Key country dynamics
      • 9.5.1.2. Regulatory framework/reimbursement structure
      • 9.5.1.3. Competitive scenario
      • 9.5.1.4. U.S. market estimates and forecasts, 2018 to 2030 (USD Million)
    • 9.5.2. Canada
      • 9.5.2.1. Key country dynamics
      • 9.5.2.2. Regulatory framework/reimbursement structure
      • 9.5.2.3. Competitive scenario
      • 9.5.2.4. Canada market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.6. Europe
    • 9.6.1. UK
      • 9.6.1.1. Key country dynamics
      • 9.6.1.2. Regulatory framework/reimbursement structure
      • 9.6.1.3. Competitive scenario
      • 9.6.1.4. UK market estimates and forecasts, 2018 to 2030 (USD Million)
    • 9.6.2. Germany
      • 9.6.2.1. Key country dynamics
      • 9.6.2.2. Regulatory framework/reimbursement structure
      • 9.6.2.3. Competitive scenario
      • 9.6.2.4. Germany market estimates and forecasts, 2018 to 2030 (USD Million)
    • 9.6.3. France
      • 9.6.3.1. Key country dynamics
      • 9.6.3.2. Regulatory framework/reimbursement structure
      • 9.6.3.3. Competitive scenario
      • 9.6.3.4. France market estimates and forecasts, 2018 to 2030 (USD Million)
    • 9.6.4. Italy
      • 9.6.4.1. Key country dynamics
      • 9.6.4.2. Regulatory framework/reimbursement structure
      • 9.6.4.3. Competitive scenario
      • 9.6.4.4. Italy market estimates and forecasts, 2018 to 2030 (USD Million)
    • 9.6.5. Spain
      • 9.6.5.1. Key country dynamics
      • 9.6.5.2. Regulatory framework/reimbursement structure
      • 9.6.5.3. Competitive scenario
      • 9.6.5.4. Spain market estimates and forecasts, 2018 to 2030 (USD Million)
    • 9.6.6. Norway
      • 9.6.6.1. Key country dynamics
      • 9.6.6.2. Regulatory framework/reimbursement structure
      • 9.6.6.3. Competitive scenario
      • 9.6.6.4. Norway market estimates and forecasts, 2018 to 2030 (USD Million)
    • 9.6.7. Sweden
      • 9.6.7.1. Key country dynamics
      • 9.6.7.2. Regulatory framework/reimbursement structure
      • 9.6.7.3. Competitive scenario
      • 9.6.7.4. Sweden market estimates and forecasts, 2018 to 2030 (USD Million)
    • 9.6.8. Denmark
      • 9.6.8.1. Key country dynamics
      • 9.6.8.2. Regulatory framework/reimbursement structure
      • 9.6.8.3. Competitive scenario
      • 9.6.8.4. Denmark market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.7. Asia Pacific
    • 9.7.1. Japan
      • 9.7.1.1. Key country dynamics
      • 9.7.1.2. Regulatory framework/reimbursement structure
      • 9.7.1.3. Competitive scenario
      • 9.7.1.4. Japan market estimates and forecasts, 2018 to 2030 (USD Million)
    • 9.7.2. China
      • 9.7.2.1. Key country dynamics
      • 9.7.2.2. Regulatory framework/reimbursement structure
      • 9.7.2.3. Competitive scenario
      • 9.7.2.4. China market estimates and forecasts, 2018 to 2030 (USD Million)
    • 9.7.3. India
      • 9.7.3.1. Key country dynamics
      • 9.7.3.2. Regulatory framework/reimbursement structure
      • 9.7.3.3. Competitive scenario
      • 9.7.3.4. India market estimates and forecasts, 2018 to 2030 (USD Million)
    • 9.7.4. Australia
      • 9.7.4.1. Key country dynamics
      • 9.7.4.2. Regulatory framework/reimbursement structure
      • 9.7.4.3. Competitive scenario
      • 9.7.4.4. Australia market estimates and forecasts, 2018 to 2030 (USD Million)
    • 9.7.5. South Korea
      • 9.7.5.1. Key country dynamics
      • 9.7.5.2. Regulatory framework/reimbursement structure
      • 9.7.5.3. Competitive scenario
      • 9.7.5.4. South Korea market estimates and forecasts, 2018 to 2030 (USD Million)
    • 9.7.6. Thailand
      • 9.7.6.1. Key country dynamics
      • 9.7.6.2. Regulatory framework/reimbursement structure
      • 9.7.6.3. Competitive scenario
      • 9.7.6.4. Thailand market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.8. Latin America
    • 9.8.1. Brazil
      • 9.8.1.1. Key country dynamics
      • 9.8.1.2. Regulatory framework/reimbursement structure
      • 9.8.1.3. Competitive scenario
      • 9.8.1.4. Brazil market estimates and forecasts, 2018 to 2030 (USD Million)
    • 9.8.2. Mexico
      • 9.8.2.1. Key country dynamics
      • 9.8.2.2. Regulatory framework/reimbursement structure
      • 9.8.2.3. Competitive scenario
      • 9.8.2.4. Mexico market estimates and forecasts, 2018 to 2030 (USD Million)
    • 9.8.3. Argentina
      • 9.8.3.1. Key country dynamics
      • 9.8.3.2. Regulatory framework/reimbursement structure
      • 9.8.3.3. Competitive scenario
      • 9.8.3.4. Argentina market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.9. MEA
    • 9.9.1. South Africa
      • 9.9.1.1. Key country dynamics
      • 9.9.1.2. Regulatory framework/reimbursement structure
      • 9.9.1.3. Competitive scenario
      • 9.9.1.4. South Africa market estimates and forecasts, 2018 to 2030 (USD Million)
    • 9.9.2. Saudi Arabia
      • 9.9.2.1. Key country dynamics
      • 9.9.2.2. Regulatory framework/reimbursement structure
      • 9.9.2.3. Competitive scenario
      • 9.9.2.4. Saudi Arabia market estimates and forecasts, 2018 to 2030 (USD Million)
    • 9.9.3. UAE
      • 9.9.3.1. Key country dynamics
      • 9.9.3.2. Regulatory framework/reimbursement structure
      • 9.9.3.3. Competitive scenario
      • 9.9.3.4. UAE market estimates and forecasts, 2018 to 2030 (USD Million)
    • 9.9.4. Kuwait
      • 9.9.4.1. Key country dynamics
      • 9.9.4.2. Regulatory framework/reimbursement structure
      • 9.9.4.3. Competitive scenario
      • 9.9.4.4. Kuwait market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 10. Competitive Landscape

  • 10.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 10.2. Company/Competition Categorization
  • 10.3. Vendor Landscape
    • 10.3.1. List of key distributors and channel partners
    • 10.3.2. Key customers
    • 10.3.3. Key company market share analysis, 2023
    • 10.3.4. Melinta Therapeutics
      • 10.3.4.1. Company overview
      • 10.3.4.2. Financial performance
      • 10.3.4.3. Disease benchmarking
      • 10.3.4.4. Strategic initiatives
    • 10.3.5. Basilea Pharmaceutica Ltd.
      • 10.3.5.1. Company overview
      • 10.3.5.2. Financial performance
      • 10.3.5.3. Disease benchmarking
      • 10.3.5.4. Strategic initiatives
    • 10.3.6. Tetraphase Pharmaceuticals
      • 10.3.6.1. Company overview
      • 10.3.6.2. Financial performance
      • 10.3.6.3. Disease benchmarking
      • 10.3.6.4. Strategic initiatives
    • 10.3.7. Theravance Biopharma
      • 10.3.7.1. Company overview
      • 10.3.7.2. Financial performance
      • 10.3.7.3. Disease benchmarking
      • 10.3.7.4. Strategic initiatives
    • 10.3.8. WOCKHARDT
      • 10.3.8.1. Company overview
      • 10.3.8.2. Financial performance
      • 10.3.8.3. Disease benchmarking
      • 10.3.8.4. Strategic initiatives
    • 10.3.9. Paratek Pharmaceuticals, Inc.
      • 10.3.9.1. Company overview
      • 10.3.9.2. Financial performance
      • 10.3.9.3. Disease benchmarking
      • 10.3.9.4. Strategic initiatives
    • 10.3.10. Seres Therapeutics
      • 10.3.10.1. Company overview
      • 10.3.10.2. Financial performance
      • 10.3.10.3. Disease benchmarking
      • 10.3.10.4. Strategic initiatives
    • 10.3.11. ACHAOGEN, INC.
      • 10.3.11.1. Company overview
      • 10.3.11.2. Financial performance
      • 10.3.11.3. Disease benchmarking
      • 10.3.11.4. Strategic initiatives
    • 10.3.12. Entasis therapeutics
      • 10.3.12.1. Company overview
      • 10.3.12.2. Financial performance
      • 10.3.12.3. Disease benchmarking
      • 10.3.12.4. Strategic initiatives
    • 10.3.13. AbbVie
      • 10.3.13.1. Company overview
      • 10.3.13.2. Financial performance
      • 10.3.13.3. Disease benchmarking
      • 10.3.13.4. Strategic initiatives
    • 10.3.14. Merck & Co. Inc.
      • 10.3.14.1. Company overview
      • 10.3.14.2. Financial performance
      • 10.3.14.3. Disease benchmarking
      • 10.3.14.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America Antibiotic Resistance market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America Antibiotic Resistance market, by disease, 2018 - 2030 (USD Million)
  • Table 4 North America Antibiotic Resistance market, by pathogen, 2018 - 2030 (USD Million)
  • Table 5 North America Antibiotic Resistance market, by drug class, 2018 - 2030 (USD Million)
  • Table 6 North America Antibiotic Resistance market, by mechanism of action, 2018 - 2030 (USD Million)
  • Table 7 North America Antibiotic Resistance market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 8 U.S. Antibiotic Resistance market, by disease, 2018 - 2030 (USD Million)
  • Table 9 U.S. Antibiotic Resistance market, by pathogen, 2018 - 2030 (USD Million)
  • Table 10 U.S. Antibiotic Resistance market, by drug class, 2018 - 2030 (USD Million)
  • Table 11 U.S. Antibiotic Resistance market, by mechanism of action, 2018 - 2030 (USD Million)
  • Table 12 U.S. Antibiotic Resistance market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 13 Canada Antibiotic Resistance market, by disease, 2018 - 2030 (USD Million)
  • Table 14 Canada Antibiotic Resistance market, by pathogen, 2018 - 2030 (USD Million)
  • Table 15 Canada Antibiotic Resistance market, by drug class, 2018 - 2030 (USD Million)
  • Table 16 Canada Antibiotic Resistance market, by mechanism of action, 2018 - 2030 (USD Million)
  • Table 17 Canada Antibiotic Resistance market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 18 Europe Antibiotic Resistance market, by region, 2018 - 2030 (USD Million)
  • Table 19 Europe Antibiotic Resistance market, by disease, 2018 - 2030 (USD Million)
  • Table 20 Europe Antibiotic Resistance market, by pathogen, 2018 - 2030 (USD Million)
  • Table 21 Europe Antibiotic Resistance market, by drug class, 2018 - 2030 (USD Million)
  • Table 22 Europe Antibiotic Resistance market, by mechanism of action, 2018 - 2030 (USD Million)
  • Table 23 Europe Antibiotic Resistance market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 24 Germany Antibiotic Resistance market, by disease, 2018 - 2030 (USD Million)
  • Table 25 Germany Antibiotic Resistance market, by pathogen, 2018 - 2030 (USD Million)
  • Table 26 Germany Antibiotic Resistance market, by drug class, 2018 - 2030 (USD Million)
  • Table 27 Germany Antibiotic Resistance market, by mechanism of action, 2018 - 2030 (USD Million)
  • Table 28 Germany Antibiotic Resistance market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 29 UK Antibiotic Resistance market, by disease, 2018 - 2030 (USD Million)
  • Table 30 UK Antibiotic Resistance market, by pathogen, 2018 - 2030 (USD Million)
  • Table 31 UK Antibiotic Resistance market, by drug class, 2018 - 2030 (USD Million)
  • Table 32 UK Antibiotic Resistance market, by mechanism of action, 2018 - 2030 (USD Million)
  • Table 33 UK Antibiotic Resistance market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 34 France Antibiotic Resistance market, by disease, 2018 - 2030 (USD Million)
  • Table 35 France Antibiotic Resistance market, by pathogen, 2018 - 2030 (USD Million)
  • Table 36 France Antibiotic Resistance market, by drug class, 2018 - 2030 (USD Million)
  • Table 37 France Antibiotic Resistance market, by mechanism of action, 2018 - 2030 (USD Million)
  • Table 38 France Antibiotic Resistance market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 39 Italy Antibiotic Resistance market, by disease, 2018 - 2030 (USD Million)
  • Table 40 Italy Antibiotic Resistance market, by pathogen, 2018 - 2030 (USD Million)
  • Table 41 Italy Antibiotic Resistance market, by drug class, 2018 - 2030 (USD Million)
  • Table 42 Italy Antibiotic Resistance market, by mechanism of action, 2018 - 2030 (USD Million)
  • Table 43 Italy Antibiotic Resistance market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 44 Spain Antibiotic Resistance market, by disease, 2018 - 2030 (USD Million)
  • Table 45 Spain Antibiotic Resistance market, by pathogen, 2018 - 2030 (USD Million)
  • Table 46 Spain Antibiotic Resistance market, by drug class, 2018 - 2030 (USD Million)
  • Table 47 Spain Antibiotic Resistance market, by mechanism of action, 2018 - 2030 (USD Million)
  • Table 48 Spain Antibiotic Resistance market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 49 Denmark Antibiotic Resistance market, by disease, 2018 - 2030 (USD Million)
  • Table 50 Denmark Antibiotic Resistance market, by pathogen, 2018 - 2030 (USD Million)
  • Table 51 Denmark Antibiotic Resistance market, by drug class, 2018 - 2030 (USD Million)
  • Table 52 Denmark Antibiotic Resistance market, by mechanism of action, 2018 - 2030 (USD Million)
  • Table 53 Denmark Antibiotic Resistance market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 54 Sweden Antibiotic Resistance market, by disease, 2018 - 2030 (USD Million)
  • Table 55 Sweden Antibiotic Resistance market, by pathogen, 2018 - 2030 (USD Million)
  • Table 56 Sweden Antibiotic Resistance market, by drug class, 2018 - 2030 (USD Million)
  • Table 57 Sweden Antibiotic Resistance market, by mechanism of action, 2018 - 2030 (USD Million)
  • Table 58 Sweden Antibiotic Resistance market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 59 Norway Antibiotic Resistance market, by disease, 2018 - 2030 (USD Million)
  • Table 60 Norway Antibiotic Resistance market, by pathogen, 2018 - 2030 (USD Million)
  • Table 61 Norway Antibiotic Resistance market, by drug class, 2018 - 2030 (USD Million)
  • Table 62 Norway Antibiotic Resistance market, by mechanism of action, 2018 - 2030 (USD Million)
  • Table 63 Norway Antibiotic Resistance market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 64 Asia Pacific Antibiotic Resistance market, by region, 2018 - 2030 (USD Million)
  • Table 65 Asia Pacific Antibiotic Resistance market, by disease, 2018 - 2030 (USD Million)
  • Table 66 Asia Pacific Antibiotic Resistance market, by pathogen, 2018 - 2030 (USD Million)
  • Table 67 Asia Pacific Antibiotic Resistance market, by drug class, 2018 - 2030 (USD Million)
  • Table 68 Asia Pacific Antibiotic Resistance market, by mechanism of action, 2018 - 2030 (USD Million)
  • Table 69 Asia Pacific Antibiotic Resistance market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 70 China Antibiotic Resistance market, by disease, 2018 - 2030 (USD Million)
  • Table 71 China Antibiotic Resistance market, by pathogen, 2018 - 2030 (USD Million)
  • Table 72 China Antibiotic Resistance market, by drug class, 2018 - 2030 (USD Million)
  • Table 73 China Antibiotic Resistance market, by mechanism of action, 2018 - 2030 (USD Million)
  • Table 74 China Antibiotic Resistance market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 75 Japan Antibiotic Resistance market, by disease, 2018 - 2030 (USD Million)
  • Table 76 Japan Antibiotic Resistance market, by pathogen, 2018 - 2030 (USD Million)
  • Table 77 Japan Antibiotic Resistance market, by drug class, 2018 - 2030 (USD Million)
  • Table 78 Japan Antibiotic Resistance market, by mechanism of action, 2018 - 2030 (USD Million)
  • Table 79 Japan Antibiotic Resistance market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 80 India Antibiotic Resistance market, by disease, 2018 - 2030 (USD Million)
  • Table 81 India Antibiotic Resistance market, by pathogen, 2018 - 2030 (USD Million)
  • Table 82 India Antibiotic Resistance market, by drug class, 2018 - 2030 (USD Million)
  • Table 83 India Antibiotic Resistance market, by mechanism of action, 2018 - 2030 (USD Million)
  • Table 84 India Antibiotic Resistance market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 85 South Korea Antibiotic Resistance market, by disease, 2018 - 2030 (USD Million)
  • Table 86 South Korea Antibiotic Resistance market, by pathogen, 2018 - 2030 (USD Million)
  • Table 87 South Korea Antibiotic Resistance market, by drug class, 2018 - 2030 (USD Million)
  • Table 88 South Korea Antibiotic Resistance market, by mechanism of action, 2018 - 2030 (USD Million)
  • Table 89 South Korea Antibiotic Resistance market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 90 Australia Antibiotic Resistance market, by disease, 2018 - 2030 (USD Million)
  • Table 91 Australia Antibiotic Resistance market, by pathogen, 2018 - 2030 (USD Million)
  • Table 92 Australia Antibiotic Resistance market, by drug class, 2018 - 2030 (USD Million)
  • Table 93 Australia Antibiotic Resistance market, by mechanism of action, 2018 - 2030 (USD Million)
  • Table 94 Australia Antibiotic Resistance market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 95 Thailand Antibiotic Resistance market, by disease, 2018 - 2030 (USD Million)
  • Table 96 Thailand Antibiotic Resistance market, by pathogen, 2018 - 2030 (USD Million)
  • Table 97 Thailand Antibiotic Resistance market, by drug class, 2018 - 2030 (USD Million)
  • Table 98 Thailand Antibiotic Resistance market, by mechanism of action, 2018 - 2030 (USD Million)
  • Table 99 Thailand Antibiotic Resistance market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 100 Latin America Antibiotic Resistance market, by region, 2018 - 2030 (USD Million)
  • Table 101 Latin America Antibiotic Resistance market, by disease, 2018 - 2030 (USD Million)
  • Table 102 Latin America Antibiotic Resistance market, by pathogen, 2018 - 2030 (USD Million)
  • Table 103 Latin America Antibiotic Resistance market, by drug class, 2018 - 2030 (USD Million)
  • Table 104 Latin America Antibiotic Resistance market, by mechanism of action, 2018 - 2030 (USD Million)
  • Table 105 Latin America Antibiotic Resistance market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 106 Brazil Antibiotic Resistance market, by disease, 2018 - 2030 (USD Million)
  • Table 107 Brazil Antibiotic Resistance market, by pathogen, 2018 - 2030 (USD Million)
  • Table 108 Brazil Antibiotic Resistance market, by drug class, 2018 - 2030 (USD Million)
  • Table 109 Brazil Antibiotic Resistance market, by mechanism of action, 2018 - 2030 (USD Million)
  • Table 110 Brazil Antibiotic Resistance market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 111 Mexico Antibiotic Resistance market, by disease, 2018 - 2030 (USD Million)
  • Table 112 Mexico Antibiotic Resistance market, by pathogen, 2018 - 2030 (USD Million)
  • Table 113 Mexico Antibiotic Resistance market, by drug class, 2018 - 2030 (USD Million)
  • Table 114 Mexico Antibiotic Resistance market, by mechanism of action, 2018 - 2030 (USD Million)
  • Table 115 Mexico Antibiotic Resistance market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 116 Argentina Antibiotic Resistance market, by disease, 2018 - 2030 (USD Million)
  • Table 117 Argentina Antibiotic Resistance market, by pathogen, 2018 - 2030 (USD Million)
  • Table 118 Argentina Antibiotic Resistance market, by drug class, 2018 - 2030 (USD Million)
  • Table 119 Argentina Antibiotic Resistance market, by mechanism of action, 2018 - 2030 (USD Million)
  • Table 120 Argentina Antibiotic Resistance market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 121 MEA Antibiotic Resistance market, by region, 2018 - 2030 (USD Million)
  • Table 122 MEA Antibiotic Resistance market, by disease, 2018 - 2030 (USD Million)
  • Table 123 MEA Antibiotic Resistance market, by pathogen, 2018 - 2030 (USD Million)
  • Table 124 MEA Antibiotic Resistance market, by drug class, 2018 - 2030 (USD Million)
  • Table 125 MEA Antibiotic Resistance market, by mechanism of action, 2018 - 2030 (USD Million)
  • Table 126 MEA Antibiotic Resistance market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 127 South Africa Antibiotic Resistance market, by disease, 2018 - 2030 (USD Million)
  • Table 128 South Africa Antibiotic Resistance market, by pathogen, 2018 - 2030 (USD Million)
  • Table 129 South Africa Antibiotic Resistance market, by drug class, 2018 - 2030 (USD Million)
  • Table 130 South Africa Antibiotic Resistance market, by mechanism of action, 2018 - 2030 (USD Million)
  • Table 131 South Africa Antibiotic Resistance market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 132 Saudi Arabia Antibiotic Resistance market, by disease, 2018 - 2030 (USD Million)
  • Table 133 Saudi Arabia Antibiotic Resistance market, by pathogen, 2018 - 2030 (USD Million)
  • Table 134 Saudi Arabia Antibiotic Resistance market, by drug class, 2018 - 2030 (USD Million)
  • Table 135 Saudi Arabia Antibiotic Resistance market, by mechanism of action, 2018 - 2030 (USD Million)
  • Table 136 Saudi Arabia Antibiotic Resistance market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 137 UAE Antibiotic Resistance market, by disease, 2018 - 2030 (USD Million)
  • Table 138 UAE Antibiotic Resistance market, by pathogen, 2018 - 2030 (USD Million)
  • Table 139 UAE Antibiotic Resistance market, by drug class, 2018 - 2030 (USD Million)
  • Table 140 UAE Antibiotic Resistance market, by mechanism of action, 2018 - 2030 (USD Million)
  • Table 141 UAE Antibiotic Resistance market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 142 Kuwait Antibiotic Resistance market, by disease, 2018 - 2030 (USD Million)
  • Table 143 Kuwait Antibiotic Resistance market, by pathogen, 2018 - 2030 (USD Million)
  • Table 144 Kuwait Antibiotic Resistance market, by drug class, 2018 - 2030 (USD Million)
  • Table 145 Kuwait Antibiotic Resistance market, by mechanism of action, 2018 - 2030 (USD Million)
  • Table 146 Kuwait Antibiotic Resistance market, by distribution channel, 2018 - 2030 (USD Million)  

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Antibiotic Resistance market: market outlook
  • Fig. 14 Antibiotic Resistance competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Penetration and growth prospect mapping
  • Fig. 18 Industry value chain analysis
  • Fig. 19 Antibiotic Resistance market driver impact
  • Fig. 20 Antibiotic Resistance market restraint impact
  • Fig. 21 Antibiotic Resistance market strategic initiatives analysis
  • Fig. 22 Antibiotic Resistance market: Disease movement analysis
  • Fig. 23 Antibiotic Resistance market: Disease outlook and key takeaways
  • Fig. 24 cUTI Antibiotic Resistance market estimates and forecast, 2018 - 2030
  • Fig. 25 CDI Antibiotic Resistance market estimates and forecast, 2018 - 2030
  • Fig. 26 ABSSSI Antibiotic Resistance market estimates and forecast, 2018 - 2030
  • Fig. 27 HABP Antibiotic Resistance market estimates and forecast, 2018 - 2030
  • Fig. 28 CABP Antibiotic Resistance market estimates and forecast, 2018 - 2030
  • Fig. 29 cIAI Antibiotic Resistance market estimates and forecast, 2018 - 2030
  • Fig. 30 BSI Antibiotic Resistance market estimates and forecast, 2018 - 2030
  • Fig. 31 Antibiotic Resistance Market: Pathogen movement Analysis
  • Fig. 32 Antibiotic Resistance market: Pathogen outlook and key takeaways
  • Fig. 33 E. coli market estimates and forecasts, 2018 - 2030
  • Fig. 34 K. pneumoniae market estimates and forecasts,2018 - 2030
  • Fig. 35 P. aeruginosa market estimates and forecasts, 2018 - 2030
  • Fig. 36 S. aureus market estimates and forecasts,2018 - 2030
  • Fig. 37 A. baumannii market estimates and forecasts, 2018 - 2030
  • Fig. 38 S. pneumoniae market estimates and forecasts,2018 - 2030
  • Fig. 39 H. influenzae market estimates and forecasts, 2018 - 2030
  • Fig. 40 C. difficile market estimates and forecasts,2018 - 2030
  • Fig. 41 E. faecium market estimates and forecasts, 2018 - 2030
  • Fig. 42 Antibiotic Resistance market: Drug Class movement analysis
  • Fig. 43 Antibiotic Resistance market: Drug Class outlook and key takeaways
  • Fig. 44 Oxazolidinones market estimates and forecasts, 2018 - 2030
  • Fig. 45 Lipoglycopeptides market estimates and forecasts,2018 - 2030
  • Fig. 46 Tetracyclines market estimates and forecasts,2018 - 2030
  • Fig. 47 Combination therapies market estimates and forecasts,2018 - 2030
  • Fig. 48 Cephalosporins market estimates and forecasts,2018 - 2030
  • Fig. 49 Others market estimates and forecasts,2018 - 2030
  • Fig. 50 Antibiotic Resistance market: Mechanism of Action movement analysis
  • Fig. 51 Antibiotic Resistance market: Mechanism of Action outlook and key takeaways
  • Fig. 52 Protein Synthesis Inhibitors market estimates and forecasts, 2018 - 2030
  • Fig. 53 Cell Wall Synthesis Inhibitors market estimates and forecasts,2018 - 2030
  • Fig. 54 RNA Synthesis Inhibitors market estimates and forecasts, 2018 - 2030
  • Fig. 55 DNA Synthesis Inhibitors market estimates and forecasts,2018 - 2030
  • Fig. 56 Others Inhibitors market estimates and forecasts,2018 - 2030
  • Fig. 57 Antibiotic Resistance market: Distribution Channel movement analysis
  • Fig. 58 Antibiotic Resistance market: Distribution Channel outlook and key takeaways
  • Fig. 59 Hospital Pharmacies market estimates and forecasts, 2018 - 2030
  • Fig. 60 Retail Pharmacies market estimates and forecasts,2018 - 2030
  • Fig. 61 Online Pharmacies market estimates and forecasts,2018 - 2030
  • Fig. 62 Global Antibiotic Resistance market: Regional movement analysis
  • Fig. 63 Global Antibiotic Resistance market: Regional outlook and key takeaways
  • Fig. 64 Global Antibiotic Resistance market share and leading players
  • Fig. 65 North America market share and leading players
  • Fig. 66 Europe market share and leading players
  • Fig. 67 Asia Pacific market share and leading players
  • Fig. 68 Latin America market share and leading players
  • Fig. 69 Middle East & Africa market share and leading players
  • Fig. 70 North America: SWOT
  • Fig. 71 Europe SWOT
  • Fig. 72 Asia Pacific SWOT
  • Fig. 73 Latin America SWOT
  • Fig. 74 MEA SWOT
  • Fig. 75 North America
  • Fig. 76 North America market estimates and forecasts, 2018 - 2030
  • Fig. 77 U.S.
  • Fig. 78 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 79 Canada
  • Fig. 80 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 81 Europe
  • Fig. 82 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 83 UK
  • Fig. 84 UK market estimates and forecasts, 2018 - 2030
  • Fig. 85 Germany
  • Fig. 86 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 87 France
  • Fig. 88 France market estimates and forecasts, 2018 - 2030
  • Fig. 89 Italy
  • Fig. 90 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 91 Spain
  • Fig. 92 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 93 Denmark
  • Fig. 94 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 95 Sweden
  • Fig. 96 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 97 Norway
  • Fig. 98 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 99 Asia Pacific
  • Fig. 100 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 101 China
  • Fig. 102 China market estimates and forecasts, 2018 - 2030
  • Fig. 103 Japan
  • Fig. 104 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 105 India
  • Fig. 106 India market estimates and forecasts, 2018 - 2030
  • Fig. 107 Thailand
  • Fig. 108 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 109 South Korea
  • Fig. 110 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 111 Australia
  • Fig. 112 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 113 Latin America
  • Fig. 114 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 115 Brazil
  • Fig. 116 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 117 Mexico
  • Fig. 118 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 119 Argentina
  • Fig. 120 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 121 Middle East and Africa
  • Fig. 122 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 123 South Africa
  • Fig. 124 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 125 Saudi Arabia
  • Fig. 126 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 127 UAE
  • Fig. 128 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 129 Kuwait
  • Fig. 130 Kuwait market estimates and forecasts, 2018 - 2030
  • Fig. 131 Market share of key market players- Antibiotic Resistance market